JPMorgan Chase & Co. reiterated their neutral rating on shares of Novartis (NYSE:NVS) in a research report sent to investors on Tuesday morning.

NVS has been the subject of several other research reports. Goldman Sachs Group reiterated a neutral rating on shares of Novartis in a research note on Wednesday, October 10th. Bank of America upgraded Novartis from an underperform rating to a buy rating and set a $74.71 price target for the company in a research note on Monday, September 10th. Zacks Investment Research downgraded Novartis from a hold rating to a sell rating in a research note on Wednesday, August 29th. Guggenheim initiated coverage on Novartis in a research note on Monday, October 8th. They set a neutral rating for the company. Finally, ValuEngine upgraded Novartis from a sell rating to a hold rating in a research note on Wednesday, September 12th. Twelve equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Novartis has a consensus rating of Hold and a consensus price target of $84.86.

Shares of Novartis stock traded down $0.02 during trading hours on Tuesday, hitting $89.22. 2,706,701 shares of the company’s stock traded hands, compared to its average volume of 3,385,154. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.20 and a quick ratio of 0.96. The firm has a market cap of $206.02 billion, a PE ratio of 18.55, a P/E/G ratio of 1.97 and a beta of 0.73. Novartis has a 12-month low of $72.30 and a 12-month high of $94.19.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Thursday, October 18th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.01. The company had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $12.88 billion. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.29 EPS. As a group, equities analysts anticipate that Novartis will post 5.17 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Stelac Advisory Services LLC bought a new position in Novartis in the 3rd quarter worth about $113,000. Columbia Asset Management bought a new position in Novartis in the 3rd quarter worth about $126,000. Howe & Rusling Inc. boosted its stake in Novartis by 50.9% in the 3rd quarter. Howe & Rusling Inc. now owns 1,705 shares of the company’s stock worth $147,000 after purchasing an additional 575 shares during the period. WESPAC Advisors SoCal LLC bought a new position in Novartis in the 3rd quarter worth about $152,000. Finally, Quad Cities Investment Group LLC bought a new position in Novartis in the 2nd quarter worth about $139,000. Institutional investors and hedge funds own 10.95% of the company’s stock.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

See Also: What is the Rule of 72?

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.